research Real-World Evidence for Baricitinib in the Treatment of Atopic Dermatitis and Alopecia Areata: Systematic Literature Review 2020–2023
Baricitinib effectively improves symptoms of atopic dermatitis and alopecia areata with few side effects.
Search
for
Sort by
Research
240-270 / 862 results 
research Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.
research Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
research The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients
JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.
research VIII International Conference "Interdisciplinary aspects of diseases of the skin and mucous membranes" 11-12th March 2022
Higher IL-31 levels are linked to worse itching in chronic kidney disease patients.
research CECHY KLINICZNE PRZEBIEGU CHORÓB UKŁADU ODDECHOWEGO WYWOŁANYCH PRZEZ SARS-COV-2 U DZIECI Z ZACHODNICH REGIONÓW BIAŁORUSI
Urban children in western Belarus had more severe COVID-19 cases in 2021.
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
research New small molecules in dermatology: for the autoimmunity, inflammation and beyond
New small molecule drugs show promise in treating complex skin diseases but need more safety research.
research Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib—A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata
A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.
research A Bibliometric Analysis of Alopecia Areata Literature over the Past 50 Years.
More research is needed on alopecia areata treatments and its psychological effects.
research The role of janus kinases in the treatment of autoimmune skin diseases
Janus kinase inhibitors show promise in treating autoimmune skin diseases.
research Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial
Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
research Keratin 6A promotes skin inflammation through JAK1-STAT3 activation in keratinocytes
Keratin 6A increases skin inflammation, suggesting it could be a target for treating certain skin diseases.
research Forging the Future: 2018 Alopecia Areata Research Summit Summary Report
The summit concluded that new treatments like Jak inhibitors show promise for Alopecia Areata and personalized approaches are needed.
research An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.
research The prostaglandin synthases, COX-2 and L-PGDS, mediate prostate hyperplasia induced by low-dose bisphenol A
Low-dose bisphenol A increases prostate size in rats by affecting certain enzymes.
research A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata
Ritlecitinib is safe and may effectively treat alopecia areata.
research 708 Promotion of hair growth in alopecia areata by topical treatment of HDAC inhibitors
HDAC inhibitors, like Vorinostat and Entinostat, can help regrow hair in alopecia areata.
research Proceedings of the Ninth World Congress for Hair Research (2015)
The 2015 Hair Research Congress concluded that stem cells, maraviroc, and simvastatin could potentially treat Alopecia Areata, topical minoxidil, finasteride, and steroids could treat Frontal Fibrosing Alopecia, and PTGDR2 antagonists could also treat alopecia. They also found that low-level light therapy could help with hair loss, a robotic device could assist in hair extraction, and nutrition could aid hair growth. They suggested that Alopecia Areata is an inflammatory disorder, not a single disease, indicating a need for personalized treatments.
research Emerging treatments in alopecia
New alopecia treatments aim for better results and fewer side effects.
research Innate type 2 immunity controls hair follicle commensalism by Demodex mites
Type 2 immunity helps control mite growth in hair follicles, preventing damage.
research Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024
In 2024, the FDA approved 27 innovative small-molecule drugs, with many offering significant treatment improvements.
research Alopecia Areata
Understanding the immune-related causes of Alopecia Areata has led to potential treatments like JAK inhibitors.
research Kaempferol enhances hair growth by regulating JAK3/STAT6 and TGF-β/Smad signaling in human dermal papilla cells and a C57BL/6 mousemodel
Kaempferol promotes hair growth and could be a natural treatment for hair loss.
research Coronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For
Effective vaccines and treatments are crucial for long-term COVID-19 control.
research Surgical Approaches for Repigmenting Vitiligo 2.0
Assessing CD8+ T cell levels before surgery may improve vitiligo treatment outcomes.
research Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study
In a 24-week multicentre study in Italy, ritlecitinib 50 mg/day was tested on 102 patients aged 12 and older with severe alopecia areata. The study found that 40.2% of patients experienced significant hair regrowth, with adolescents responding better (48.6%) than adults (21.9%). The mean Severity of Alopecia Tool (SALT) score improved from 86.2 to 40.8, and improvements were noted in trichoscopic signs, quality of life, and hair regrowth on eyebrows, eyelashes, and nails. The treatment was generally well tolerated, with mild adverse events like acne and headache, and only one severe case of anaemia. Overall, ritlecitinib was effective and safe, particularly for adolescents.
research Molecular crosstalk between lncRNA H19, miR-29a, and JAK2/STAT3 signaling in alopecia areata: a preliminary study
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research SARS-CoV-2 Non-Structural Proteins and Their Roles in Host Immune Evasion
SARS-CoV-2 proteins help the virus avoid the immune system, delaying response and increasing inflammation.